The strengthened balance sheet removes near-term dilution risk and funds pipeline catalysts. Key events to watch: Phase 2 BOS data in Q1 2027 and Phase 2b PH-ILD data in Q1 2028. The S-3/A filed 9 days ago registers existing shares for resale, not a new capital raise, so no immediate overhang.
Price Chart
Executive Summary
Quince Therapeutics reported Q2 2026 results highlighting a strengthened balance sheet with $116M cash following the Orphai acquisition and concurrent $115M private placement. Net loss widened to $75.5M ($12.31 per share) due to one-time acquisition and restructuring charges, but the company now has cash runway through end of 2028 and a late-stage pulmonary pipeline anchored by LAM-001 with multiple near-term catalysts.
Key Financial Metrics
Key Facts
- Cash and cash equivalents of $116M as of June 30, 2026, up from $17.8M at year-end 2025
- Net loss of $75.5M for Q2 2026 vs $16.0M in Q2 2025, driven by $59M acquired IPR&D and $9.1M one-time stock-based compensation
- Net loss per share of $12.31 (basic and diluted) vs $68.75 in Q2 2025 (adjusted for reverse splits)
- Completed Orphai Therapeutics acquisition and closed $115M private placement in May 2026
- LAM-001 Phase 2b PH-ILD trial initiated; topline data expected Q1 2028
- Phase 2 BOS trial fully enrolled; data expected Q1 2027
- Phase 2 SAPH trial anticipated to begin late 2026 with data expected Q4 2028
- Weighted-average shares outstanding for Q2 2026: 6,132,845 (basic and diluted)
Financial Impact
Cash position increased ~6.5x to $116M, providing operational runway through end of 2028. Net loss increased 4.7x YoY due to one-time acquisition and restructuring costs.
Risk Factors
- Clinical trial failure or disappointing data for LAM-001 in any indication
- Regulatory hurdles for LAM-001 development and approval
- Competition from other mTOR inhibitors or pulmonary hypertension therapies
- Potential dilution from warrant exercises (up to $83M additional proceeds)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345285 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 8-K | $31.32 $28.59 | ▲ +8.72% | ▲ +7.51% | $30.20 (+3.58%) |
Aug 25, 2026 5w ago | EFFECT | $30.93 $32.11 | ▼ −3.82% | ▼ −4.35% | $30.20 (+2.36%) |
Aug 14, 2026 7w ago | 8-K | $31.34 awaiting T+5 | awaiting T+5 | — | $30.20 (−3.64%) |
Aug 14, 2026 7w ago | Press Release | $31.34 awaiting T+5 | awaiting T+5 | — | $30.20 (−3.64%) |
Aug 5, 2026 8w ago | S-3/A | $28.88 $31.26 | ▲ +8.24% | ▲ +7.89% | $30.20 (+4.57%) |
Jun 11, 2026 16w ago | 3 | $0.9337 $0.9451 | ▲ +1.22% | ▲ +0.55% | $30.20 (+3134.44%) |
May 18, 2026 19w ago | 8-K | $19.90 $24.00 | ▲ +20.60% | ▲ +18.99% | $30.20 (+51.76%) |
Apr 27, 2026 22w ago | DEFA14A | $24.60 $24.60 | · 0.00% | ▼ −1.70% | $30.20 (+22.76%) |
Apr 9, 2026 25w ago | 8-K | $1.24 $1.34 | ▲ +8.06% | ▲ +4.88% | $30.20 (+2335.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access